Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma

NCT05344664 | Unknown Phase 1 DMC

• 1 other identifier: HXYT-I-017
• Study Type: interventional
• Target: 12
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a single-center, single-arm, open-label Phase I study to evaluate the safety and efficacy of GPC3-CAR-T cell immunotherapy in the treatment of hepatocellular carcinoma.

Outcome Measures

Primary Outcomes (1)

• Percentage of adverse events

  Percentage of participants with adverse events.

  3months

Interventions

GPC3-CAR-T cells BIOLOGICAL

The patients will receive one dose of GPC3-CAR-T.The dosage ranges from3×10\^6 to 1×10\^8 CAR-T+/kg.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥ 18 years old, ≤ 65 years old, gender is not limited; 2. Hepatocellular carcinoma diagnosed by histological/cytological examination, or liver cirrhosis who meet the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Study of Liver Diseases (AASLD), are not suitable for surgery or local treatment, and have received first-line standardized systemic treatment Later failure or intolerance or refusal to accept standard treatment; Definition of intolerance: According to CTCAEv5.0, hematological toxicity of grade ≥IV or non-hematological toxicity of grade ≥III or damage to major organs such as heart, liver, kidney, etc. of grade ≥II occurs during treatment; Definition of treatment failure: disease progression (PD) during treatment or recurrence after the end of treatment (including postoperative recurrence).
• \. The tumor tissue samples were positive for GPC3 by immunohistochemistry (IHC); 4. At least one measurable lesion (according to RECIST1.1), the long diameter of non-lymph node lesions ≥ 1.0cm, or the short diameter of lymph node lesions ≥ 1.5cm, and intrahepatic lesions require arterial phase enhancement imaging.
• \. The Barcelona Clinic Liver Cancer (BCLC) staging system is C stage or B stage that is not suitable for local therapy or fails local therapy; 6. Child-Pugh score A or good B (≤7 points); 7. ECOG score 0-1 within one week before enrollment; 8. Expected survival period ≥ 12 weeks; 9. Normal function of major organs: Blood routine: white blood cell count ≥3×109/L, absolute neutrophil count (ANC) ≥1.5×109/L; hemoglobin (Hb) ≥85g/L; platelet count ≥75×109/L (14 Days without blood transfusion, not corrected with drugs such as hematopoietic factors); Blood biochemistry: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 times the upper limit of normal (ULN), total bilirubin (TBIL) ≤ 2.5 times the upper limit of normal (ULN); creatinine (cCr) ≤1.5 times the upper limit of normal value (ULN); 10. Women of childbearing age must have a negative serological pregnancy test during the screening period and within 14 days before the reinfusion of cells; and are willing to use reliable methods of contraception during the test and 12 months after cell infusion; for partners of childbearing age Female male subjects, should undergo surgical sterilization, or agree to use a reliable method of contraception during the trial and for 12 months after cell reinfusion.
• \. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up.

You may not qualify if:

• Active infection that is difficult to control;
• HIV antibody positive, syphilis serological test positive;
• Past or current hepatic encephalopathy (HE);
• Have a history of organ transplantation or are waiting for organ (including liver transplantation) transplantation (including hematopoietic stem cell transplantation);
• Those with organ failure:
• Heart: New York Heart Association (NYHA) cardiac function class C-D;
• Kidney: renal failure stage and uremia stage;
• Lung: symptoms of respiratory failure;
• Brain: people with impaired consciousness.
• Are receiving systemic steroid therapy (≥0.5mg/kg/day methylprednisolone or equivalent);
• The toxicity or complications caused by previous intervention or treatment have not recovered to grade 2 or below (except for alopecia);
• Imaging results show: \>50% of the liver has been occupied by tumor, or hepatic portal vein tumor thrombus, or mesenteric/inferior vena cava-tumor thrombus invasion;
• Previously received other genetically modified T cell products (such as CAR-T or TCR-T), or treatment targeting GPC3;
• Received anti-PD-1/PD-L1 monoclonal antibody treatment within 4 weeks before apheresis; received local or systemic treatment such as surgery, interventional therapy, radiotherapy, and ablation for the research disease within 2 weeks before apheresis Systemic chemotherapy; or received immunotherapy such as thymosin, interferon, or any Chinese herbal medicine or proprietary Chinese medicine for liver cancer control within 1 week before apheresis; or received sorafenib, regorafenone within 1 week before apheresis Targeted drug therapy such as ni and lenvatinib;
• Clinically significant, uncontrollable ascites (defined as: physical examination with positive signs of ascites or ascites that needs to be controlled by intervention (only those with ascites shown by imaging but not requiring intervention can be included));

Sponsors & Collaborators

• Peking University: lead

Central Study Contacts

Lin Shen, PhD

CONTACT

13911219511; doctorshenlin.@sina.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 19, 2022
• First Posted: April 25, 2022
• Study Start: April 14, 2022
• Primary Completion: October 14, 2024
• Study Completion: February 1, 2025
• Last Updated: April 25, 2022

Record last verified: 2022-04